Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058

• Main Authors: Lucas,G.M., Beauchamp,G., Aramrattana,A., Shao,Y., Liu,W., Fu,L., Jackson,J.B., Celentano,D.D., Richardson,P.D., Metzger,D.S.
• Format: Article
• Published: Elsevier 2015
• Subjects: Medicine (miscellaneous); Health Policy
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857797951&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38200
• Institution: Chiang Mai University

Background: Buprenorphine/naloxone (BUP/NX) is not licenced for use in China or Thailand and there was little clinical experience with this drug combination in these countries at the inception of HIV Prevention Trial Network (HPTN) 058, a randomized trial comparing risk reduction counselling combine...